 A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33 Watson Laboratories, Inc., USA to Reference Product Mirvaso brimonidine topical gel, 0.33 Galderma Laboratories, L.P., USA in Patients with Moderate to Severe Facial Erythema Associated with Rosacea 